The median PFS survival was 11.2 and 7.7 months for the PD-L1 positive population (as defined by ≥1% of immune cells IHC-staining positive within the tested tumor area), tested with atezolizumab plus bevacizumab or sunitinib alone, respectively. The gene discussed is CD274; the disease is neoplasm.